EM1507D "Immunotherapy: A New Era in Cancer Treatment" (IM GR-071015)

Drugs that manipulate the immune system have recently been shown to have durable clinical responses in patients with melanoma. In this protocol and presentation, we discuss the scientific and clinical milestones that led to that achievement. Each of these milestones was surrounded by controversy and there are lessons to be learned in how the challenges were overcome.

Protocol

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Learn the experimental rationale for cancer immunosurveillance
  • Learn how CTLA-4 was discovered and the rationale for targeting CTLA-4 in cancer
  • Review clinical trials for immunotherapeutic agents
Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
07/16/2015
Course expires: 
08/15/2015
Cost:
$0.00

Deepak Nijhawan, M.D., Ph.D.
Assistant Professor
Division of Hematology and Oncology
Department of Biochemistry

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Accreditation Period

Course opens: 
07/16/2015
Course expires: 
08/15/2015

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Hardware/software requirements: Activities should be run with recent versions of comon browsers, including Internet Explorer, Firefox and Google Chrome.